These investigators further confirmed that the enhanced anti-proliferation effect mediated by CQ and LY are not related to BRAF-activating mutations (BRAF-activating mutations occur in 50–70% of melanoma cases) as shown by real-time PCR analysis. This evidence concerns the gene BRAF and melanoma.